IL260024B - Method for assessing the response to pd-1/pdl-1 targeting drugs - Google Patents

Method for assessing the response to pd-1/pdl-1 targeting drugs

Info

Publication number
IL260024B
IL260024B IL260024A IL26002418A IL260024B IL 260024 B IL260024 B IL 260024B IL 260024 A IL260024 A IL 260024A IL 26002418 A IL26002418 A IL 26002418A IL 260024 B IL260024 B IL 260024B
Authority
IL
Israel
Prior art keywords
pdl
drug therapy
targeted drug
evaluating response
evaluating
Prior art date
Application number
IL260024A
Other languages
English (en)
Hebrew (he)
Other versions
IL260024A (en
Original Assignee
Roussy Inst Gustave
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussy Inst Gustave filed Critical Roussy Inst Gustave
Publication of IL260024A publication Critical patent/IL260024A/en
Publication of IL260024B publication Critical patent/IL260024B/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL260024A 2015-12-18 2018-06-14 Method for assessing the response to pd-1/pdl-1 targeting drugs IL260024B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15307050 2015-12-18
PCT/EP2016/081485 WO2017103147A1 (en) 2015-12-18 2016-12-16 Method for assessing the response to pd-1/pdl-1 targeting drugs

Publications (2)

Publication Number Publication Date
IL260024A IL260024A (en) 2018-07-31
IL260024B true IL260024B (en) 2021-07-29

Family

ID=55129471

Family Applications (1)

Application Number Title Priority Date Filing Date
IL260024A IL260024B (en) 2015-12-18 2018-06-14 Method for assessing the response to pd-1/pdl-1 targeting drugs

Country Status (5)

Country Link
US (1) US11137404B2 (https=)
JP (1) JP6762363B2 (https=)
KR (1) KR102378298B1 (https=)
IL (1) IL260024B (https=)
WO (1) WO2017103147A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101980003B1 (ko) * 2017-09-14 2019-05-17 건국대학교 글로컬산학협력단 면역체크포인트의 발현을 억제하기 위한 물질을 포함하는 나노입자 전달체
KR102216725B1 (ko) * 2017-12-29 2021-02-17 연세대학교 산학협력단 면역 항암 요법에 대한 치료 반응 예측 방법
WO2019159825A1 (ja) * 2018-02-14 2019-08-22 国立大学法人名古屋大学 抗pd-1抗体/抗pd-l1抗体療法の効果を予測するバイオマーカー
GB201805876D0 (en) * 2018-04-09 2018-05-23 Francis Crick Institute Ltd Method
JP2022533012A (ja) * 2019-04-30 2022-07-21 エックスセル・バイオサイエンシズ・インコーポレイテッド 細胞表現型を調節するための系および方法
WO2020239558A1 (en) 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
TW202327595A (zh) 2021-10-05 2023-07-16 美商輝瑞大藥廠 用於治療癌症之氮雜內醯胺化合物的組合
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist
KR20230125672A (ko) * 2022-02-21 2023-08-29 사회복지법인 삼성생명공익재단 암 환자에 대한 면역관문억제제의 반응성 예측용 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling

Also Published As

Publication number Publication date
JP6762363B2 (ja) 2020-09-30
US11137404B2 (en) 2021-10-05
KR20180115262A (ko) 2018-10-22
WO2017103147A1 (en) 2017-06-22
IL260024A (en) 2018-07-31
KR102378298B1 (ko) 2022-03-23
JP2019500870A (ja) 2019-01-17
US20180364241A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
IL260024B (en) Method for assessing the response to pd-1/pdl-1 targeting drugs
IL283561B (en) Methods for treating ocular diseases
IL257091B (en) Targeted oligonucleotides
EP3314027A4 (en) THERAPEUTIC OLIGONUCLEOTIDES
EP3368656A4 (en) TARGETED CANCER THERAPY
IL257252A (en) Methods of treating fgf21-associated disorders
IL281293A (en) Methods of treating hyperalgesia
BR112017018054A2 (pt) métodos para a cobertura de sequências de ácidos nucleicos direcionadas
PL3978070T3 (pl) Urządzenie magnetyczne do stymulacji terapeutycznej
DK3107563T3 (da) Glycomålrettede terapeutiske midler
EP3349677C0 (en) ELECTROSURGICAL DEVICE
HRP20190165T1 (hr) Genska terapija za fabryjevu bolest
DK3234134T3 (da) Målrettet rna-redigering
HUE051767T2 (hu) Új eljárások oligonukleotidok elõállítására
DK3153148T3 (da) Apparat til seksuel stimulation
DK3262066T4 (da) Genterapi
MA39483A (fr) Agents thérapeutiques cibles
EP3310303A4 (en) TORSION STABILIZED ENDOPROSTHESIS DEVICE
EP3333833A4 (en) TECHNOLOGY SIMULATOR
HUE049511T2 (hu) Módszer magok stimulálására
SI4119569T1 (sl) Konjugirane protismiselne spojine za uporabo v terapiji
DK3310432T3 (da) Indretning til effektiv ikke-invasiv to-trinsneurostimulation
DK3355890T3 (da) Humane plasmakallikreininhibitorer
IL253549B (en) Antibody-urease conjugates for therapeutic purposes
EP3309163A4 (en) SUBSTITUTED DIHYDROPYRROLO PYRAZOL DERIVATIVE